Clinical Trial Update: Sirolimus and Thymoglobulin to Prevent Kidney Transplant Rejection [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating sirolimus with thymoglobulin to prevent kidney transplant rejection has completed; results posted in 2010.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kidney Failure

Drugs mentioned

• Sirolimus (Sirolimus)
• Thymoglobulin (rabbit anti-thymocyte globulin)

Snippet

Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Conditions: Kidney Failure | Phase 2 | Status: COMPLETED | Results posted: 2010-02-11